Tuoxin Pharmaceutical Group Co.,Ltd.

301089

CNE100004YC3

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-19 pm EDT			5-day change	1st Jan Change
39.14 ^CNY	+0.49%		-6.54%	-27.53%

Apr. 22	Tuoxin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 22	Tuoxin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Approves Cash Dividend for 2021

May 17, 2022 at 03:36 pm EDT

Xinxiang Tuoxin Pharmaceutical Co.,Ltd. at the AGM held on May 16, 2022, approved Cash dividend per 10 shares (tax included) of CNY 1.00000000 for 2021.

Latest news about Tuoxin Pharmaceutical Group Co.,Ltd.

Tuoxin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 22	CI
Tuoxin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 22	CI
Tuoxin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Tuoxin Pharmaceutical Group Co.,Ltd.(XSEC:301089) added to S&P Global BMI Index	23-09-18	CI
Tuoxin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Approves the Cash Dividend for the Year 2022, Payment Date: 06 June 2023	23-05-31	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. has Changed its Name to Tuoxin Pharmaceutical Group Co., Ltd	23-05-26	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Approves the Cash Dividend for the Year 2022	23-05-18	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for the Year of 2022	23-04-26	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Xinxiang Tuoxin Pharma to Form New Chemical Products Subsidiary	23-03-17	MT
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-20	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-22	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Announces Final Cash Dividend on A Shares for the Year 2021, Payable on May 25, 2022	22-05-18	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Approves Cash Dividend for 2021	22-05-17	CI
Tuoxin Pharmaceutical to Free Up 1.5 Million Shares For Trading; Shares Tank 5%	22-04-26	MT
Xinxiang Tuoxin Pharma’s 2021 Profit Plunges 42% as Sales Slip 5%	22-04-25	MT
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Proposes Final Dividend for 2021	22-04-22	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-21	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-21	CI
Xinxiang Changtong Industrial Co., Ltd. announced that it has received CNY 17 million in funding from Xinxiang Tuoxin Pharmaceutical Co.,Ltd.	21-11-21	CI
Xinxiang Changtong Industrial Co., Ltd. announced that it expects to receive CNY 17 million in funding from Xinxiang Tuoxin Pharmaceutical Co.,Ltd.	21-11-09	CI
Xinxiang Pharmaceutical Co., Ltd. announced that it expects to receive CNY 235.4564 million in funding from Xinxiang Tuoxin Pharmaceutical Co.,Ltd.	21-11-09	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. has completed an IPO in the amount of CNY 601.965 million.	21-10-22	CI

Chart Tuoxin Pharmaceutical Group Co.,Ltd.

Duration

Period

Chart Tuoxin Pharmaceutical Group Co.,Ltd.

More charts

Tuoxin Pharmaceutical Group Co Ltd, formerly Xinxiang Tuoxin Pharmaceutical Co Ltd, is a Chinese company mainly engaged in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates. The Company's main products include pyrimidine series, purine series, nucleotide series, nucleoside series and other series of nucleoside (acid) products, including citicoline sodium, ribavirin, inosine, acyclovir, azvudine, cytosine, 5-fluorocytosine, cytidine, uridine and other raw materials and pharmaceutical intermediates. Its products are mainly used in the fields of virus, anti-tumor and nervous system drugs. The Company mainly distributes its products in domestic market and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
TUOXIN PHARMACEUTICAL GROUP CO.,LTD.	-27.53%	682M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.91%	44.12B
OTSUKA HOLDINGS CO., LTD.	+23.33%	22.71B
SANDOZ GROUP AG	+18.22%	15.15B
CIPLA LIMITED	+12.22%	13.61B
ZYDUS LIFESCIENCES LIMITED	+62.24%	13.34B
ONO PHARMACEUTICAL CO., LTD.	-8.76%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+15.65%	5.63B

Generic Pharmaceuticals

Tuoxin Pharmaceutical Group Co.,Ltd.

Equities

301089

CNE100004YC3

Pharmaceuticals

Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Approves Cash Dividend for 2021

Latest news about Tuoxin Pharmaceutical Group Co.,Ltd.

Chart Tuoxin Pharmaceutical Group Co.,Ltd.

Company Profile

Income Statement Evolution

Sector Generic Pharmaceuticals